Head of funding for 16 years steps up at Nordic supra

◆ Dutch issuer brings new euro benchmark at last, with social label ◆ Most recent euro line opened over 10 months ago ◆ Peers' bonds helpful to pricing given BNG's absence

There's been a lack of ESG labelled FIG issuance in March, despite this year's volume being higher than last year

Have the chance to put forward your opinion and shape this year’s Bond Awards winners.

BNG deal 'most exciting' while Eurofima will test long-dated demand

◆ Defensive structure for nervous market ◆ Largest book on a busy day for FIG issuance ◆ ABN keeps position of leading bank EuGB issuer

State of New Hampshire's innovative bond gets Ba2 rating

Shares in company, which manufactures underwater mine disposal drones, have risen by close to 50% this year

Renewables can make Europe’s capital markets less vulnerable to energy price shocks

High demand from institutional and retail investors for maker of Patriot missile components

Book to open on Monday, close on Thursday in latest express IPO

Submarine mast maker's IPO raised €132.8m

Central banks in the region have stepped in with support and lenders are thought unlikely to let sub debt extend

African issuers are dominating CEEMEA issuance

A prolonged oil shock will hurt airlines, but a Covid-style industry collapse is a long way off

The company's curve has massively outperformed the South African sovereign this month

Like Angola's, yields on Sasol bonds have fallen since the Middle East war began

Higher prices and concessions mean many issuers will wait for better days

I don’t need to work, but I’m tempted to go back

Primary market for public sector unlikely to see large transactions until after Easter, reckon bankers

War uncertainty and volatile rates have halted European unsecured bank issuance in euros

BioNTech, the German biopharmaceuticals company, is selling 5.5m American Depositary Receipts (ADRs) on the Nasdaq through a share sale and a rights issue. The company, which is working with Pfizer to develop a vaccine for Covid-19, is the latest issuer to hit the market in a wave of biotech ECM issuance — but buyers are being warned against being too eager, reports Sam Kerr.

The International Finance Facility for Immunisation (IFFIm) was set up in 2006 to provide funding to Gavi, the Vaccine Alliance, itself a public/private sector partnership, to expedite the vaccination of children in the poorest countries against endemic infectious diseases. Doris Herrera-Pol, IFFIm board member and former director of global capital markets at the World Bank, spoke to GlobalCapital about the role the capital markets can play in the development and deployment of a Covid-19 vaccine.

Investors have got a fever, and the only cure is more pharma. Biotech equity issuance is surging, in line with rising stock prices in the secondary market, as stock pickers pan for the company that will cure Covid-19, among other maladies. But this is more speculating than investing and many are going to catch a cold chasing around a risky sector that is starting to look a lot like the dot-com bubble.